2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Radionuclide-Drug Conjugates (RDCs)

Radionuclide-Drug Conjugates (RDCs)

ADC-Related Custom Services

Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.

Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P5128
    DOTA-JR11
    		98.81%
    DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research. DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-JR11
  • HY-134418
    NOTA
    		≥98.0%
    NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research.
    NOTA
  • HY-P9983
    Lintuzumab
    		98.09%
    Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice.
    Lintuzumab
  • HY-155483
    PSMA-BCH
    		99.93%
    PSMA-BCH (NOTA-PSMA) is a NOTA-conjugated precursor. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools.
    PSMA-BCH
  • HY-P10131
    3BP-3940
    		99.96%
    3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases.
    3BP-3940
  • HY-W250574
    NOTA-bis(tBu)ester
    		≥98.0%
    NOTA-bis(tBu)ester (NOTA-bis(t-Butyl ester)), a NOTA derivative, is a bifunctional chelator that can be used for drug coupling.
    NOTA-bis(tBu)ester
  • HY-164725
    FAPI-mFS
    		99.78%
    FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu. FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    FAPI-mFS
  • HY-P5018
    NOTA-AE105
    		98.91%
    NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by 64Cu and 68Ga. 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation. NOTA-AE105 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NOTA-AE105
  • HY-157977
    DOTA-GA-maleimide
    		99.26%
    DOTA-GA-maleimide is a bifunctional chelator containing a DOTA macrocycle chelator, a GA linker, and a maleimide reactive group. DOTA-GA-maleimide can achieve radiolabeling of proteins by forming a stable coordination complex between the DOTA macrocycle and radioactive metal ions (such as 111In) through the specific binding of maleimide to protein thiol groups. DOTA-GA-maleimide can be used for SPECT imaging studies of MMP activity-related cancers.
    DOTA-GA-maleimide
  • HY-P99326
    Tositumomab
    Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.
    Tositumomab
  • HY-P10137
    Satoreotide
    		98.88%
    Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing.
    Satoreotide
  • HY-W087187
    DOTAGA-anhydride
    		99.80%
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.
    DOTAGA-anhydride
  • HY-153550
    PSMA-1007
    		99.79%
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    PSMA-1007
  • HY-136641
    NOTA-FAPI
    		99.26%
    NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor. NOTA-FAPI can be used as a probe for FAP-targeted tumour imaging. NOTA-FAPI has good tumour detection efficacy and excellent imaging quality.
    NOTA-FAPI
  • HY-P5362
    NODAGA-LM3
    		99.33%
    NODAGA-LM3 can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NODAGA-LM3
  • HY-W046355
    Fmoc-D-Dap(Boc)-OH
    		99.56%
    Fmoc-D-Dap(Boc)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as DOTA-modified peptides and their metal chelates with cancer diagnostic effects.
    Fmoc-D-Dap(Boc)-OH
  • HY-160116
    α-Synuclein aggregate binder 1
    		98.11%
    α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia.
    α-Synuclein aggregate binder 1
  • HY-100138
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)
    		≥98.0%
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a metal chelator precursor containing a DOTA macrocyclic structure. DOTA can form highly stable complexes with metal ions (such as 68Ga, 177Lu) through four nitrogen atoms and four carboxylic acid groups to mediate targeted delivery of radionuclides. The tert-butyl ester group (tBu ester) of 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) also protects the carboxylic acid group during synthesis, and forms a free carboxyl group after deprotection reaction for coupling with targeting molecules (such as antibodies, peptides). 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) may be combined with tumor pre-targeting systems through bioorthogonal reactions (such as reverse electron demand Diels-Alder reaction) to study radioactive imaging or therapy of tumor tissues, and is mainly used in tumor pre-targeting research in the field of nuclear medicine.
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)
  • HY-W614269
    DOTA-GA(tBu)4
    		≥98.0%
    DOTA-GA(tBu)4 is a DOTA derivative similar to NOTA-GA. DOTA-GA(tBu)₄ is a tert-butyl-protected chelating agent used for the synthesis of DOTA-GA-TATE conjugates. The structure of DOTA-GA(tBu)4 allows for convenient conjugation to the N-terminus of peptides. DOTA-GA(tBu)4 can be used in research on medical imaging and diagnosis.
    DOTA-GA(tBu)4
  • HY-D2363
    DOTA.SA.FAPi TFA
    		99.26%
    DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC50 of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC50 of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with 68Ga, and used for research about cancer. DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA.SA.FAPi TFA
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.